AGR.L

Assura Plc
Assura plc - Notice of Results & Retail Investor Presentation
31st October 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3003K
Assura PLC
31 October 2024
 

31 October 2024

Assura plc

Notice of Interim Results & Retail Investor Presentation

Assura plc ("the Company"), the UK's leading diversified healthcare REIT will announce results for the six months ended 30 September 2024 on Thursday 14 November 2024.

A presentation for analysts and investors, immediately followed by a Q&A with members of the senior management team, can be viewed at 10.00 am GMT at the following link:

https://brrmedia.news/AGR_HY_24

Additional Investor Presentation for Retail Investors via Investor Meet Company

Assura plc is also pleased to announce that Jonathan Murphy and Jayne Cottam will provide a live presentation relating to the Interim Results via Investor Meet Company on 15 Nov 2024, 1.00pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 14 Nov 2024, 9.00am GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Assura via:

https://www.investormeetcompany.com/assura-plc/register-investor

Investors who already follow Assura on the Investor Meet Company platform will automatically be invited.

- Ends -

 

For more information, please contact:

Assura plc
 David Purcell, Investor Relations Director

Tel: 0161 515 2043
 Email: Investor@assura.co.uk

FGS Global

Gordon Simpson
 Grace Whelan

Tel: 0207 251 3801
 Email: Assura@fgsglobal.com

 

Notes to Editors

Assura plc is the UK's leading diversified healthcare REIT. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.

A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7 billion and has a strong track record of growing financial returns and dividends for shareholders.

At Assura, we BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORWPGMGUUPCGMU]]>
TwitterFacebookLinkedIn